About: The challenges in developing effective canine infectious respiratory disease vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The challenges in developing effective canine infectious respiratory disease vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The challenges in developing effective canine infectious respiratory disease vaccines
Creator	Brownlie, Joe Mitchell, Judy Correspondence, Judy Mitchell,
Source	Medline; PMC
abstract	OBJECTIVES: Canine infectious respiratory disease (CIRD) is a disease of multifactorial aetiology, where multiple pathogens act sequentially or synergistically to cause disease. It is common within large dog populations, such as those in re‐homing or training kennels. Vaccines are vital in its management of CIRD, but they often fail to prevent disease. Recently, a number of novel pathogens have been identified in CIRD outbreaks and represent new targets for vaccination. KEY FINDINGS: Innate immune responses provide a vital first line of defence against the infectious agents involved in the development of CIRD. Once breeched, adaptive mucosal immunity is necessary to prevent infection and limit spread. Current vaccines target only a few of the agents involved in CIRD. Evidence, from the limited amount of published data, indicates that although vaccinating against these agents reduces infection rates, duration of shedding and severity of disease, it does not induce sterilising immunity; and this has important consequences for the management of the disease, and the future of CIRD vaccine development. SUMMARY: In the process of considering the development of novel CIRD vaccines, this paper focuses on the immunological mechanisms that provide protection for the respiratory tract, the current recommendations for canine vaccination, and the challenges surrounding existing CIRD vaccines, and their future development.
has issue date	2015-03-03(xsd:dateTime)
bibo:doi	10.1111/jphp.12380
bibo:pmid	25736813
has license	no-cc
sha1sum (hex)	61c9ab1d4b7162b712975c3ba666e6f2a4f1ea0c
schema:url	https://doi.org/10.1111/jphp.12380
resource representing a document's title	The challenges in developing effective canine infectious respiratory disease vaccines
has PubMed Central identifier	PMC7166679
has PubMed identifier	25736813
schema:publication	J Pharm Pharmacol
resource representing a document's body	covid:61c9ab1d4b7162b712975c3ba666e6f2a4f1ea0c#body_text
is schema:about of	named entity 'prevent' named entity 'provide' named entity 'vaccine' named entity 'reduces' named entity 'limited' named entity 'development' named entity 'Review' named entity 'vaccination' named entity 'development' named entity 'duration' named entity 'respiratory disease' named entity 'IS A' named entity 'PHARMACY' named entity 'LARGE' named entity 'THEIR' named entity 'TARGETS' named entity 'VACCINES' named entity 'MANAGEMENT' named entity 'THESE' covid:arg/61c9ab1d4b7162b712975c3ba666e6f2a4f1ea0c named entity 'IFN-γ' named entity 'pattern recognition receptors' named entity 'pathogens' named entity 'antigens' named entity 'Th1' named entity 'multivalent vaccine' named entity 'protein' named entity 'dog' named entity 'innate immune responses' named entity 'RNA' named entity 'pathogens' named entity 'pathogen' named entity 'antiviral' named entity 'DCs' named entity 'pathogens' named entity 'non-specific immunity' named entity 'epithelial cells' named entity 'canine' named entity 'gastro-intestinal' named entity 'pathogen' named entity 'columnar epithelial cells' named entity 'vaccine efficacy' named entity 'rabies' named entity 'development' named entity 'vaccines' named entity 'involved' named entity 'pathogens' named entity 'respiratory disease' named entity 'adaptive immune responses' named entity 'IgA' named entity 'epithelial' named entity 'DCs' named entity 'mucus membranes' named entity 'present antigen' named entity 'human parainfluenza virus' named entity 'mucus production' named entity 'humoral' named entity 'canine' named entity 'pharynx' named entity 'MALT' named entity 'apoptosis' named entity 'mucosal surfaces' named entity 'DCs' named entity 'antigenic' named entity 'antibodies' named entity 'significant difference' named entity 'vaccination' named entity 'respiratory disease' named entity 'cytotoxic T-lymphocytes' named entity 'intranasal' named entity 'cellular components' named entity 'vaccine' named entity 'DCs' named entity 'Type I interferons' named entity 'IgA' named entity 'subunit vaccines' named entity 'T-lymphocytes' named entity 'epithelial barrier'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software